Bio-Techne Appoints Rupert Vessey to Board of Directors

JUNE 25, 2019 MINNEAPOLIS, June 25, 2019 /PRNewswire/ — Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company’s Board of Directors as an independent director.  Dr. Vessey’s appointment brings the total number of Bio-Techne Board members to nine. Rupert Vessey, MA, BM BCh, FRCP, DPhil is currently the President of Global Research... Read more

FDA Grants Breakthrough Device Designation to Bio-Techne’s ExoDx™ Prostate Intelliscore™ (EPI) Test

JUNE 17, 2019 MINNEAPOLIS, June 17, 2019 /PRNewswire/ — Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) test, making it the first exosome-based liquid biopsy test to receive a Breakthrough Device Designation. This designation not only validates the clinical importance of... Read more

Bio-Techne Receives Approval to Offer the ExoDx™ Prostate IntelliScore™ (EPI) Test in New York State

JUNE 13, 2019 The EPI prostate biopsy rule-out test is now available in every state MINNEAPOLIS, June 13, 2019 /PRNewswire/ — Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help... Read more

Bio-Techne to Acquire B-MoGen Biotechnologies Inc.

JUNE 04, 2019 MINNEAPOLIS, June 4, 2019 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. “We are very pleased to include the B-MoGen technology in Bio-Techne’s expanding portfolio... Read more

Elpiscience and Bio-Techne Announce Strategic Collaboration

APRIL 22, 2019 SHANGHAI and MINNEAPOLIS, April 22, 2019 /PRNewswire/ — Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the terms of the agreement, Elpiscience will have access to multiple antibodies from Bio-Techne’s extensive product portfolio for use in the development of preclinical, clinical, and commercial... Read more

Bio-Techne and NanoString Partner to Co-Develop Integrated Workflow for RNA Spatial Profiling

Integrated Workflow Combines NanoString’s GeoMx DSP High-Plex RNA Assays and Bio-Techne’s Highly Sensitive RNAscope Imaging Reagent Portfolio SEATTLE and MINNEAPOLIS, March 28, 2019 (GLOBE NEWSWIRE) — Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic... Read more

Bio-Techne Scores a Trio of CiteAb 2019 Awards

MARCH 05, 2019 MINNEAPOLIS, March 5, 2019 /PRNewswire/ — Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored with three prestigious 2019 CiteAb Awards. The CiteAb Awards celebrate the very best suppliers and individuals in the research sector worldwide.  Bio-Techne’s Advanced Cell Diagnostics (ACD) brand received... Read more

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

FEBRUARY 26, 2019 MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ — Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality... Read more

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

FEBRUARY 26, 2019 MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ — Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality... Read more

Bio-Techne Introduces 48-digoxigenin Cartridge for the Ella Platform

JANUARY 29, 2019 MINNEAPOLIS, Jan. 29, 2019 /PRNewswire/ — Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows users to perform high-quality immunoassays in under 90 minutes without manual intervention. This innovative workflow enables companies to speed up their research and empowers employees to spend their... Read more